Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nuclear Medicine and Biology

• Publication date

  2017-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.nucmedbio.2016.10.004PMID 27837664
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standardisation and precise determination of the half-life of (44)Sc.

  2016cited by this paper
• 44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations

  2016cited by this paper
• Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET.

  2016cited by this paper
• Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.

  2016cited by this paper
• Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT

  2016cited by this paper
• Scandium-44 DOTATOC PET/CT: First in-human molecular imaging of neuroendocrine tumors and possible perspectives for Theranostics

  2015cited by this paper
• Cyclotron production of (44)Sc: From bench to bedside.

  2015cited by this paper
• First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

  2014cited by this paper
• Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates.

  2014cited by this paper
• Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice

  2014cited by this paper
• Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.

  2014cited by this paper
• Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo.

  2014cited by this paper
• Matching chelators to radiometals for radiopharmaceuticals.

  2014cited by this paper
• Matching the Decay Half-Life with the Biological Half-Life: ImmunoPET Imaging with 44Sc-Labeled Cetuximab Fab Fragment

  2014cited by this paper
• Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with (44m/44)Sc and experimental evidence of the feasibility of an in vivo PET generator.

  2014cited by this paper
• 64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats.

  2014cited by this paper
• A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.

  2014cited by this paper
• 44Sc: An Attractive Isotope for Peptide-Based PET Imaging

  2014cited by this paper
• Promises of Cyclotron-Produced 44Sc as a Diagnostic Match for Trivalent β−-Emitters: In Vitro and In Vivo Study of a 44Sc-DOTA-Folate Conjugate

  2013cited by this paper
• Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts

  2013cited by this paper
• Imaging of Protein Synthesis: In Vitro and In Vivo Evaluation of 44Sc-DOTA-Puromycin

  2013cited by this paper
• In Vivo and In Vitro Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors

  2013cited by this paper
• Scandium-44: benefits of a long-lived PET radionuclide available from the (44)Ti/(44)Sc generator system.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Treatment of HER2-positive breast cancer: current status and future perspectives

  2012cited by this paper
• 44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?

  2012cited by this paper
• Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals.

  2011cited by this paper
• Protein scaffold-based molecular probes for cancer molecular imaging

  2011cited by this paper
• PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference

  2011cited by this paper
• HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis

  2011cited by this paper
• A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue

  2010cited by this paper
• Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules

  2010cited by this paper
• HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

  2010cited by this paper
• Radionuclide molecular imaging using Affibody molecules.

  2010cited by this paper
• Monoclonal antibodies: versatile platforms for cancer immunotherapy

  2010cited by this paper
• Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

  2010cited by this paper
• Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.

  2010cited by this paper
• Peptide-based probes for targeted molecular imaging.

  2010cited by this paper
• On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model

  2009cited by this paper
• Molecular imaging to select cancer therapy and evaluate treatment response.

  2009cited by this paper
• Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!

  2009cited by this paper
• Slow Internalization of Anti-HER2 Synthetic Affibody Monomer 111In-DOTA-ZHER2:342-pep2 : Implications for Development of Labeled Tracers

  2008cited by this paper
• Antibodies for Molecular Imaging of Cancer

  2008cited by this paper
• 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression

  2008cited by this paper
• Imaging of HER-2 overexpression in tumors for guiding therapy.

  2008cited by this paper
• Molecular targeting with peptides or peptide-polymer conjugates: just a question of size?

  2005cited by this paper
• Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapy.

  2002cited by this paper
• Radiometal‐Labelled Macrocyclic Chelator‐Derivatised Somatostatin Analogue with Superb Tumour‐Targeting Properties and Potential for Receptor‐Mediated Internal Radiotherapy

  1999cited by this paper
• Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.

  1993cited by this paper

• Investigating the Theranostic Potential of Elementally Matched [43Sc]Sc-PSMA-617 and [47Sc]Sc-PSMA-617.

  2026cites this paper
• Research Progress on Major Medical Radionuclide Generators

  2025cites this paper
• Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy.

  2025cites this paper
• Endorsing Titanium–Scandium Radionuclide Generator for PET and Positronium Imaging

  2025cites this paper
• Unveiling the chemistry of antibody conjugation for enhanced PET imaging: Current trends and future directions.

  2024cites this paper
• Experimental Uses of Positronium and Potential for Biological Applications

  2024influential citation
• Transition and Post-Transition Radiometals for PET Imaging and Radiotherapy.

  2024cites this paper
• Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals.

  2023cites this paper
• Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer

  2022cites this paper
• Evaluation of hydroxamate-based resins towards a more clinically viable 44Ti/44Sc radionuclide generator.

  2022cites this paper
• Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems.

  2021cites this paper
• Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers

  2021cites this paper
• Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons

  2021cites this paper
• Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements

  2021influential citation
• State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET

  2021cites this paper
• Targeting and imaging of HER2 overexpression tumor with a new peptide-based 68Ga-PET radiotracer.

  2020cites this paper
• Image quality analysis of 44Sc on two preclinical PET scanners: a comparison to 68Ga

  2020cites this paper
• Affibody Molecules as Targeting Vectors for PET Imaging

  2020cites this paper
• Prospects and Clinical Perspectives of Total-Body PET Imaging Using Plastic Scintillators.

  2020cites this paper
• Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18.

  2020cites this paper
• In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model.

  2019cites this paper
• PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules

  2019cites this paper
• Engineering of binding functions into proteins.

  2019cites this paper
• Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts

  2019cites this paper
• Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application

  2018cites this paper
• Radioactive Main Group and Rare Earth Metals for Imaging and Therapy.

  2018cites this paper
• Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications

  2018cites this paper
• SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin.

  2018cites this paper
• Proton-induced production and radiochemical isolation of 44Ti from scandium metal targets for 44Ti/44Sc generator development.

  2017influential citation
• Syddansk Universitet The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated

  2017cites this paper
• Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer

  2017cites this paper
• The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule

  2017cites this paper
• Affibody Molecules in Biotechnological and Medical Applications.

  2017cites this paper
• - I m a g i n g s i n g P a s t i c S c i n t i l l a t o r s

  year unknowncites this paper